INVESTOR PRESENTATION JUNE 2020 X4 PHARMACEUTICALS INVESTOR DECK FORWARD LOOKING STATEMENTS The statements herein are subject to various risks and uncertainties. These risks and uncertainties include, without limitation, the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of mavorixafor or other product candidates; the risk that costs required to develop mavorixafor or other product candidates or to expand our oper ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Candice Ellis - Director of Corporate Communications & Investor Relations Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Joel Beatty - Citi Swayampakula Ramakanth - H.C. Wainwright Laura Christianson - Cowen Trevor Allred - Oppenheimer Sahil Kazmi - B. Riley FBR Arlinda Lee - Canaccord Operator Greetings, and w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2019 Results Conference Call March 12, 2020 8:30 AM ET Company Participants Candice Ellis - IR Paula Ragan - CEO Lynne Kelley - CMO Adam Mostafa - CFO Conference Call Participants Stephen Willey - Stifel Arlinda Lee - Canaccord Genuity Marc Frahm - Cowen Joel Beatty - Citi Swayampakula Ramakanth - H.C. Wainwright Alex Heller - Oppenheimer Zegbeh Jallah - ROTH Capital Partners Operator Greetings and welcome to X4 Pharmaceuticals Fourth Quarter and Full Year 2019 Busi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per ...

INVESTOR PRESENTATION MARCH 2020 X 4 P H A R M A C E U T I C A L S I N V E S T O R D E C K FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, a ...

For the transition period from __________ to __________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38295 X4 PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-3181608 (State or other jurisd ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (857) 529-8300 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38295 ARSANIS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...